Trial Search Results

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

This study will test an experimental combination of the drugs Mylotarg and 5-azacitidine in the hopes of finding a treatment that may be effective against Acute Myeloid Leukemia that has come back after treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

University of California, San Diego

Collaborator: Celgene Corporation

Stanford Investigator(s):


  • Drug: 5-Azacitidine
  • Drug: Gemtuzumab ozogamicin


Phase 1/Phase 2


Inclusion Criteria:

   - Diagnosis of Relapsed AML

   - Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and life expectancy
   > 3 months

   - ≥ 18 years old

   - Previously untreated for current AML relapse

   - Adequate organ function

   - Written informed consent

Exclusion Criteria:

   - Pregnant or breast-feeding women

   - Growth factors that support platelet or white cell number or function must not have
   been administered within the past 7 days

   - Currently receiving another investigational drug

   - Currently receiving other anti-cancer agents

   - Uncontrolled infection

   - HIV positive

   - Received previous therapy with either Mylotarg or 5-azacitidine

Ages Eligible for Study

18 Years - 90 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting